

# Câncer de Esôfago

## **5-Fluorouracil + Cisplatina + Radioterapia**

5-Fluorouracil: 1.000 mg/m<sup>2</sup>/dia IV infusão contínua D1 a D4

Cisplatina: 75 mg/m<sup>2</sup> IV no D1

Repetir nas semanas 1, 5, 8, e 11 Ref. (1)

## **5-Fluorouracil + Cisplatina + Radioterapia**

### **(Esquema Hopkins/Yale)**

5-Fluorouracil: 225 mg/m<sup>2</sup>/dia IV infusão contínua D1 a D30

Cisplatina: 20 mg/m<sup>2</sup>/dia IV D1–5 e 26–30

Paclitaxel: 135 mg/m<sup>2</sup> IV em 24 horas D1

Cisplatina: 75 mg/m<sup>2</sup> IV D2

a cada 21 dias por 3 ciclos Ref. (2)

## **5-Fluorouracil + Cisplatina**

5-Fluorouracil: 1.000 mg/m<sup>2</sup>/dia IV infusão contínua D1 a D5.

Cisplatina: 100 mg/m<sup>2</sup> IV D1

Semanas 1, 5, 8, e 11 Ref. (3)

## **Irinotecano + Cisplatina**

Irinotecano: 65 mg/m<sup>2</sup> IV semanalmente por 4 semanas

Cisplatina: 30 mg/m<sup>2</sup> IV semanalmente por 4 semanas

a cada 6 semanas Ref. (4)

## **Paclitaxel + Cisplatina**

Paclitaxel: 200 mg/m<sup>2</sup> IV em 24 horas D1

Cisplatina: 75 mg/m<sup>2</sup> IV D2

a cada 21 dias Ref. (5)

## **Paclitaxel**

Paclitaxel: 250 mg/m<sup>2</sup> IV em 24 horas D1

a cada 21 dias Ref. (6)

## **ECF**

Epirrubicina: 50mg/m<sup>2</sup> IV D1

Cisplatina: 60mg/m<sup>2</sup> IV D1

5-Fluorouracil: 225 mg/m<sup>2</sup>/dia IV D1 ao D21

a cada 21 dias

Ref. (7)

## **Oxaliplatina e Capecitabina**

Oxaliplatina: 30mg/m<sup>2</sup> IV D1

Capecitabina: 1700mg/m<sup>2</sup>/dia VO D1 a D14

a cada 21 dias

Ref. (8)

## **EP**

Cisplatina: 30 mg/m<sup>2</sup> IV D1 a D4

Etoposide: 120 mg/m<sup>2</sup> IV D1 a D4

a cada 28 dias

Ref. (9)

## **Paclitaxel, Carboplatina e 5-Fluorouracil**

Paclitaxel: 200 mg/m<sup>2</sup> IV D1 e D22

Carboplatina: AUC6 IV D1 e D22

5-Fluorouracil: 225 mg/m<sup>2</sup>/dia IV contínuo D1 a D42

\* Regime aplicado junto com a radioterapia no pré-operatório.

A cirurgia é realizada 4 a 5 semanas após o término do tratamento combinado.

Ref. (10)

## **Gencitabina, 5-Fluorouracil e Leucovorin**

Gencitabina: 1000 mg/m<sup>2</sup> IV D1, D8 e D15

5-Fluorouracil: 600 mg/m<sup>2</sup> IV D1, D8 e D15

Leucovorin: 25 mg/m<sup>2</sup> IV D1, D8 e D15 a cada 28 dias

Ref. (11)

1. Herskovic A, *et al.* Combined chemotherapy eradiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326:1593–1598.
2. Heath EI, *et al.* Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy porsquamous cell and adenocarcinoma of the esophagus. *J Clin Oncol* 2000;18:868–876.
3. Kies MS, *et al.* Cisplatin e5-fluorouracil in the primary management of squamous esophageal cancer. *Cancer* 1987;60:2156–2160.
4. Ilson DH, *et al.* Phase II trial of semanalmente irinotecan plus cisplatin in first line advanced esophageal cancer. *J Clin Oncol* 1999;17: 3270–3275.
5. Ilson DH, *et al.* Phase II trial of paclitaxel, fluorouracil, ecisplatin in patients with advanced carcinoma of the esophagus. *J Clin Oncol* 1998;16:1826–1834.
6. Ajani JA, *et al.* Paclitaxel in the treatment of carcinoma of the esophagus. *Semin Oncol* 1995;22 (Suppl 6):35–40.
7. Cunningham D *et al.* Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. *N Engl J Med.* 2006; 355:11-20.
8. Jatoi A *et al.* Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. *Ann Oncol.* 2006. 17; 29-34.
9. Hejna M, Kornek GV *et al.* Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma. *Cancer* 1996 15(78): 1646-50.
10. Melucci M,*et al.* Preoperative therapy with concurrent paclitaxel/ carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. *Canicer J* 2003;9:251-60.
11. Morgan-Meadows, *et al.* A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. *Oncology* 2005;69:130-4.